CEL-SCI To Participate in Ascendiant’s Quarterly Management Discussion Series Today, Friday February 20 at 11 Am Eastern Time
February 20 2015 - 8:00AM
Business Wire
CEL-SCI Corporation (NYSE MKT:CVM), a late stage cancer
immunotherapy company, announced that Geert Kersten, Chief
Executive Officer, will participate in Ascendiant’s Quarterly
Management Discussion Series teleconference today, Friday, February
20, 2015, at 11 AM ET.
Interested parties may access the call by dialing
+1-719-457-6209 and entering passcode 216781. A replay webcast link
will be available on the investor relations section of
www.cel-sci.com shortly after the call concludes.
About CEL-SCI Corporation
CEL-SCI’s work is focused on finding the best way to activate
the immune system to fight cancer and infectious diseases. CEL-SCI
believes that the best way may be to activate the immune system of
patients before they have received surgery, radiation and/or
chemotherapy. Its lead investigational immunotherapy Multikine
(Leukocyte Interleukin, Injection) is currently being studied in a
pivotal Phase III clinical trial against head and neck cancer. If
the study endpoint, which is a 10% improvement in overall survival
of the subjects treated with Multikine treatment regimen as
compared to subjects treated with current standard of care only is
satisfied, the study results will be used to support applications
which will be submitted to regulatory agencies in order to receive
from these agencies commercial marketing approvals for Multikine in
major markets around the world. Additional clinical indications for
Multikine which are being investigated include cervical dysplasia
in HIV/HPV co-infected women, and the treatment of peri-anal warts
in HIV/HPV co-infected men and women. A Phase I trial of the former
indication has been completed at the University of Maryland. The
latter indication is now in a Phase I trial in conjunction with the
U.S. Navy under a CRADA (Cooperative Research and Development
Agreement).
CEL-SCI is also developing its LEAPS technology for the
treatment of pandemic influenza and as a potential therapeutic
vaccine against rheumatoid arthritis. The Company has recently
received a Phase I SBIR Grant from the National Institutes of
Health to develop LEAPS as a potential treatment for RA with
researchers from Rush University Medical Center in Chicago,
Illinois. The Company has operations in Vienna, Virginia, and
in/near Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
CEL-SCI CorporationGavin de Windt, 703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Apr 2023 to Apr 2024
